NCT03975907 2024-03-12
Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)
CARsgen Therapeutics Co., Ltd.
Phase 1/2 Unknown
Clinical Trials
51 trialsNCT01754402 2024-02-20
Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma
Duke University
Phase 1/2 Unknown
NCT06223646 2024-01-25
A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory Multiple Myeloma
Novatim Immune Therapeutics (Zhejiang) Co., Ltd.
Phase 1/2 Unknown
NCT04714827 2023-12-29
Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma
Shanxi Province Cancer Hospital
Phase 1/2 Unknown
NCT05280275 2023-12-01
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible
Hellenic Society of Hematology
Phase 1/2 Unknown
NCT06126237 2023-11-13
A Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma
Keymed Biosciences Co.Ltd
Phase 1/2 Unknown
NCT04942067 2023-10-25
APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma
Ascentage Pharma Group Inc.
Phase 1/2 Unknown
NCT04309981 2023-08-28
Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/Refractory Multiple Myeloma to Proteasome Inhibitors, Immunomodulators and Anti-CD38 Antibody.
Institut d'Investigacions Biomèdiques August Pi i Sunyer
Phase 1/2 Unknown
NCT03090659 2023-06-12
LEGEND-2
Nanjing Legend Biotech Co.
Phase 1/2 Unknown
NCT05857982 2023-05-15
Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed/Refractory Multiple Myeloma
Second Affiliated Hospital of Soochow University
Phase 1/2 Unknown
NCT05749133 2023-04-20
Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2 Unknown
NCT04272151 2023-04-18
Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma
Chongqing Precision Biotech Co., Ltd
Phase 1/2 Unknown
NCT04674514 2023-03-07
APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma
Ascentage Pharma Group Inc.
Phase 1/2 Unknown
NCT05739188 2023-02-23
Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Phase 1/2 Unknown
NCT05672420 2023-01-05
Umbilical Cord Derived Mesenchymal Stem Cells for Treatment-induced Myelosuppression in Hematologic Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1/2 Unknown
NCT04935580 2022-08-03
Study of FasT CAR-T GC012F Injection in High Risk TE NDMM Patients
Shanghai Changzheng Hospital
Phase 1/2 Unknown
NCT05150522 2021-12-09
B Cell Maturation Antigen Targeted CAR-T Cells in Treatment With Relapsed and Refractory Multiple Myeloma
Shenzhen University General Hospital
Phase 1/2 Unknown
NCT05066646 2021-11-23
FUMANBA-1
Nanjing IASO Biotechnology Co., Ltd.
Phase 1/2 Unknown
NCT03670173 2021-05-19
Safety and Efficacy Assessments of Osalmid in Multiple Myeloma
Shanghai 10th People's Hospital
Phase 1/2 Unknown
NCT04891744 2021-05-18
Selinexor in Combination With Thalidomide and Dexamethasone in RRMM
Sichuan University
Phase 1/2 Unknown
NCT03795597 2021-04-26
BuMelCarAuto
Loyola University
Phase 1/2 Unknown
NCT04762745 2021-02-21
The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple Myeloma
Sun Yat-sen University
Phase 1/2 Unknown
NCT03638206 2019-12-11
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
Shenzhen BinDeBio Ltd.
Phase 1/2 Unknown
NCT03018405 2019-09-19
THINK
Celyad Oncology SA
Phase 1/2 Unknown
NCT03271632 2019-09-19
Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma
Shenzhen Geno-Immune Medical Institute
Phase 1/2 Unknown
NCT02954445 2019-06-25
A Clinical Research of BCMA-Targeted CAR-T in B Cell Malignancies
Southwest Hospital, China
Phase 1/2 Unknown
NCT03940833 2019-05-07
Clinical Research of Adoptive BCMA CAR-NK Cells on Relapse/Refractory MM
Asclepius Technology Company Group (Suzhou) Co., Ltd.
Phase 1/2 Unknown
NCT03767751 2018-12-07
A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma
Chinese PLA General Hospital
Phase 1/2 Unknown
NCT03607643 2018-07-31
A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies
Leaf Vertical Inc.
Phase 1/2 Unknown
NCT01792102 2018-03-05
Safety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib for Progressive Multiple Myeloma
Oncotherapeutics
Phase 1/2 Unknown
NCT03322735 2017-12-29
Study of BCMA CAR-T in Multiple Myeloma
Henan Cancer Hospital
Phase 1/2 Unknown
NCT03091933 2017-12-06
GLIDE
Ciusss de L'Est de l'Île de Montréal
Phase 1/2 Unknown
NCT02488382 2017-10-17
Lonquek for Autologous Stem Cell Mobilization
Sheba Medical Center
Phase 1/2 Unknown
NCT02519114 2017-02-10
Haploidentical Bone Marrow Stem Cell Transplantation in Patients With Multiple Myeloma
Maastricht University Medical Center
Phase 1/2 Unknown
NCT01522872 2016-06-02
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
Threshold Pharmaceuticals
Phase 1/2 Unknown
NCT01541332 2016-03-10
Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma
Oncotherapeutics
Phase 1/2 Unknown
NCT01886976 2016-01-28
CART-138
Chinese PLA General Hospital
Phase 1/2 Unknown
NCT01812096 2015-08-18
MM
The First Affiliated Hospital of Soochow University
Phase 1/2 Unknown
NCT00800059 2015-07-27
TMI-ASCT
Ottawa Hospital Research Institute
Phase 1/2 Unknown
NCT02145715 2015-06-26
MUKsix
University of Leeds
Phase 1/2 Unknown
NCT02248402 2014-09-25
Vax-DC/MM
Chonnam National University Hospital
Phase 1/2 Unknown
NCT01435720 2014-09-11
Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)
Senesco Technologies, Inc.
Phase 1/2 Unknown
NCT02007811 2014-03-26
B-cell therapy
University of Erlangen-Nürnberg Medical School
Phase 1/2 Unknown
NCT00334932 2014-01-10
Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple Myeloma
National Cancer Institute (NCI)
Phase 1/2 Unknown
NCT00006466 2013-12-18
Beta Alethine in Treating Patients With Myeloma
National Cancer Institute (NCI)
Phase 1/2 Unknown
NCT01695590 2013-06-04
Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma
Prolexys Pharmaceuticals
Phase 1/2 Unknown
NCT01686386 2013-04-05
Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, for the Treatment of Patients With Relapsed Myeloma
Gruppo Italiano Studio Linfomi
Phase 1/2 Unknown
NCT01010243 2012-05-30
MM03
University of Regensburg
Phase 1/2 Unknown
NCT00431990 2011-08-12
A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma
Peter MacCallum Cancer Centre, Australia
Phase 1/2 Unknown
NCT01002703 2011-08-12
Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma
University of Leipzig
Phase 1/2 Unknown